Eisai Global
Manufacturing · Japan · 10K+ Employees
View Company Info for Free
Overview
Headquarters
4-6-10 Koishikawa Bunkyo-ku, Tokyo, Toky...Phone Number
+81 338173700Website
www.eisai.comRevenue
$5.1 BillionStock Symbol
ESAIYIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
8
1
2
1
1
1
About Eisai Global
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence in countries such as the United States, Japan, China, and the United Kingdom. The company maintains a significant focus on research and development in the pharmaceutical sector, with particular emphasis on patient-centered healthcare solutions. Eisai's business model encompasses both business-to-business and business-to-consumer operations, reflecting its comprehensive approach to healthcare delivery and pharmaceutical development.Explore more
Eisai Global Org Chart
PF
Vice President and General Manager
SY
Vice President
KA
Vice President
JK
Vice President, Clinical Development
JZ
Vice President and Head of MBE Division
SS
Vice President, China Business Japan, Asia Fi...
MK
Strategy Vice President, Supply Chain
LO
Vice President, Quality Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eisai Global your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Eisai Global has new funding data
Eisai Global, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Eisai Global launches new products
Check out if Eisai Global is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Eisai Global has recently received funding, and reach out quickly before it becomes old news!
Click to see if Eisai Global had a recent Job posting/layoffs
Earning: See what the market has to say on Eisai Global recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Eisai Global
Recommended Actions
Reach out to Masked Content who joined Eisai Global as Masked Content
Find 2 more new buyers
Compare Similar Companies to Eisai Global
Compare insights from companies similar to Eisai Global, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Eisai Global
$5.1B
10K+
Public
-
1941
Tatsuyuki YasunoChairman & CEO & Eisai Inc Region President (Americas)
$48.5B
10K+
Public
$4B
1887
IC
Imara CharlesVice President, Chief of Staff, Global Product Development & Supply
Company Profile Activity
Activity Insights
Eisai Global is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eisai Global is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eisai Global.
Eisai Global Tech Stack
A closer look at the technologies used by Eisai Global
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Eisai Global News & Media
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)...FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 TOKYO and CAMBRIDGE, Mass., July 13, 2026 /PRNewswire/ --...LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partnersEisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
TOKYO, July 2, 2026 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer’s disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer’s Association International Conference® 2026 (AAIC®) from July 12-15 in London and online. Eisai will presen
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Eisai Global
Sign Up For FreeTo access detailed company insights
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence... Read More
